Patents by Inventor Titus Kretzschmar

Titus Kretzschmar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding Members to PD-L1
    Publication number: 20230235061
    Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: August 30, 2022
    Publication date: July 27, 2023
    Applicant: Cell Medica, Inc.
    Inventors: Abdijapar SHAMSHIEV, Titus KRETZSCHMAR, Mariam DROSTE, Douglas PHILLIPS
  • Antibodies Against IL-1 Beta
    Publication number: 20230203151
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: August 5, 2022
    Publication date: June 29, 2023
    Applicant: Cell Medica, Inc.
    Inventors: Annemarie HONEGGER, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Stefanie GRABULOVSKI
  • DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20220323380
    Abstract: The present invention is inter alia concerned with a combination (i) a first compound selected from the group consisting of a norepinephrine-dopamine reuptake inhibitor (NDRI), a catecholamine and pharmaceutically acceptable salts thereof, (ii) a second compound selected from the group consisting of vitamin D3, calcifediol, calcitriol, vitamin D2, ercalcidiol and ercalcitriol, and (iii) a third compound selected from the group consisting of vitamin K1, vitamin K2 and vitamin K3, for use in the treatment of an inflammatory disease, preferably multiple sclerosis.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 13, 2022
    Inventors: Titus Kretzschmar, Christa Zwicky
  • Binding members to PD-L1
    Patent number: 11434294
    Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 6, 2022
    Assignee: Cell Medica, Inc.
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
  • Nucleic acids encoding antibodies against IL-1 beta
    Patent number: 11407824
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 9, 2022
    Assignee: Cell Medica, Inc.
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
  • ANTIBODY TO HUMAN IL-1 BETA
    Publication number: 20220220195
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: January 28, 2022
    Publication date: July 14, 2022
    Inventors: Stefanie Grabulovski, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Thorsten Alexander SCHAFER
  • Antibody to human IL-1 beta
    Patent number: 11267884
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 8, 2022
    Assignee: Cell Medica Inc.
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • BINDING MEMBERS TO TNF ALPHA
    Publication number: 20210332119
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: April 23, 2021
    Publication date: October 28, 2021
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • Nucleic acids encoding binding members to TNF alpha
    Patent number: 10995138
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 4, 2021
    Assignee: Cell Medica Inc.
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • ANTIBODIES AGAINST IL-1 BETA
    Publication number: 20200362028
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: February 6, 2020
    Publication date: November 19, 2020
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
  • ANTIBODY TO HUMAN IL-1 BETA
    Publication number: 20200239565
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 30, 2020
    Inventors: Stefanie GRABULOVSKI, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Thorsten Alexander SCHAFER
  • Nucleic acid encoding antibody to human IL-1 beta
    Patent number: 10626171
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: April 21, 2020
    Assignee: Cell Medica Switzerland AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • BINDING MEMBERS TO TNF ALPHA
    Publication number: 20190144532
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 16, 2019
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • TNF alpha antibody or fragment thereof and methods of use
    Patent number: 10233238
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: March 19, 2019
    Assignee: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • BINDING MEMBERS TO PD-L1
    Publication number: 20190055312
    Abstract: The present invention relates to anti-PD-L1 binding members and in particular to monovalent, high potency PD-L1-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and inflammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Applicant: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
  • MODIFIED CELLS FOR IMMUNOTHERAPY
    Publication number: 20190048085
    Abstract: The present invention relates to engineered immune cells expressing antigen receptors, such as a T cell receptor (TCR) or a chimeric antigen receptor (CAR), as well as antibody targeting PD-L1. Also provided are related nucleic acids, vectors, compositions and method for enhancing the immune response towards cancers and pathogens.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 14, 2019
    Inventors: Gianpietro Dotti, Elisa Landoni, Abdijapar Shamshiev, Titus Kretzschmar, Miriam Droste, Douglas Phillips
  • ANTIBODY TO HUMAN IL-1 BETA
    Publication number: 20180362642
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 20, 2018
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • Method of inhibiting human IL-1 beta by administering an antibody to human IL-1 beta
    Patent number: 10077302
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: September 18, 2018
    Assignee: Cell Medica Switzerland AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
  • ANTIBODIES AGAINST IL-1 BETA
    Publication number: 20180258165
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: February 14, 2018
    Publication date: September 13, 2018
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
  • Antibodies against IL-1 beta
    Patent number: 9914772
    Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 13, 2018
    Assignee: Cell Medica Switzerland AG
    Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski